Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-IL-6 chimeric monoclonal antibody

(AN-tee ... ky-MEER-ik MAH-noh-KLOH-nul AN-tee-BAH-dee)
A drug used to treat a rare condition called multicentric Castleman disease in patients who do not have HIV or human herpesvirus 8. It is also being studied in the treatment of some types of cancer and other conditions. Anti-IL-6 chimeric monoclonal antibody binds to a protein called interleukin-6 (IL-6), which is made by some white blood cells and other cells in the body. Anti-IL-6 chimeric monoclonal antibody may help reduce inflammation and stop the growth of cancer cells or abnormal blood cells. It is a type of monoclonal antibody. Also called cCLB8, CNTO 328, siltuximab, and Sylvant.
More Information
Search NCI's Dictionary of Cancer Terms